---
layout: post
title: "海思科：创新药注射用HSK36273获临床试验批准"
date: 2022-04-10 16:01:18 +0800
categories: cailianshe
tags: 财联社新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/0.002653" data-code="002653|0|2" data-code2="002653|0|6|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=0.002653&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 002653_0" data-code="K 002653|0|2" data-code2="K 002653|0|6|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>海思科公告，获得创新药注射用HSK36273《药物临床试验批准通知书》。注射用HSK36273为我公司研发的静脉用抗凝血药物，临床拟用于血液透析及术中患者的全身抗凝。 <br /></p><p class="em_media">（文章来源：财联社）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202204102337464020>

[返回财联社新闻](//finews.withounder.com/category/cailianshe.html)｜[返回首页](//finews.withounder.com/)